|Bid||39.79 x 800|
|Ask||39.92 x 800|
|Day's Range||39.72 - 40.40|
|52 Week Range||29.17 - 46.55|
|Beta (5Y Monthly)||1.08|
|PE Ratio (TTM)||10.80|
|Forward Dividend & Yield||0.72 (1.75%)|
|Ex-Dividend Date||Aug 28, 2020|
|1y Target Est||45.25|
Fresenius Medical (FMS) continues to gain traction from its broad range of dialysis products and services. However, intense competition remains a woe.
Fresenius Medical Care, the world’s leading provider of dialysis products and services, today announced the launch of the organization’s first World Patient Safety Day initiative to raise awareness of the importance of ultrapure dialysis fluid for developing economies across Asia Pacific. On 17 September each year, the World Health Organization (WHO), international partners and all countries commemorate World Patient Safety Day: a day that aims to increase global awareness of the need to protect patients in healthcare settings. Fresenius Medical Care Asia Pacific has chosen this important day to highlight the crucial role that ultrapure dialysis fluid (UPDF) plays in reducing morbidity and mortality in hemodialysis (HD) patients,1 and to launch a multi-year initiative providing ongoing healthcare professional education to increase the uptake of high-quality dialysis fluid.
Last month CtW Investment Group urged Fresenius Medical Care AG to add diverse directors to its board. The concern about underrepresentation of minority groups is leading to new data-gathering efforts and legislation.